Clinical Trial Finder

DISEASE CHARACTERISTICS:

• - Diagnosis of neoplastic meningitis secondary to leukemia, lymphoma (including AIDS-related lymphoma), or solid tumor (including primary CNS tumors or carcinomas of unknown primary site), defined by 1 of the following criteria: - Cerebral spinal fluid (CSF) cell count > 5/μL AND evidence of blast cells on cytospin or by cytology (for patients with leukemia or lymphoma) - Presence of tumor cells on cytospin or cytology OR unequivocal presence of meningeal disease by MRI (for patients with solid tumor) - No conventional therapy for neoplastic meningitis exists.

• - Patients with CNS leukemia or lymphoma must be refractory to conventional therapy, including radiotherapy (i.e., second or greater relapse) - Patients with CNS leukemia or lymphoma must have had a negative bone marrow aspiration within the past 2 weeks.

• - No clinical evidence of obstructive hydrocephalus.

• - No compartmentalization of CSF flow by radioisotope indium In 111 or technetium Tc 99 DTPA flow study.

• - No ventriculoperitoneal or ventriculoatrial shunt unless patient is completely shunt-independent.

• - No impending spinal cord compression or other CNS involvement (e.g., acute visual loss secondary to optic nerve involvement) requiring emergent local radiotherapy.

PATIENT CHARACTERISTICS: Age.

• - 3 to 21.

Performance status.

• - Lansky 60-100% (≤ 16 years of age) OR.

• - Karnofsky 60-100% (> 16 years of age) Life expectancy.

• - Not specified.

Hematopoietic.

• - Not specified.

Hepatic.

• - Not specified.

Renal.

• - Calcium ≥ 7 mg/dL.

Other.

• - Not pregnant or nursing.

• - Negative pregnancy test.

• - Fertile patients must use effective contraception.

• - Sodium 125-150 mmol/L.

• - Magnesium ≥ 0.7 mmol/L.

• - Must have or be willing to have an intraventricular access device (i.e., Ommaya reservoir) - No uncontrolled infection.

• - HIV-positive patients with AIDS-related lymphomatous meningitis are eligible.

• - No other significant uncontrolled systemic medical illness that would preclude study participation.

PRIOR CONCURRENT THERAPY: Biologic therapy.

• - Recovered from prior biologic therapy or immunotherapy.

Chemotherapy.

• - Recovered from prior chemotherapy.

• - At least 1 week since prior intra-colony stimulating factory (CSF) chemotherapy (2 weeks for liposomal cytarabine) - At least 3 weeks since prior systemic chemotherapy for leptomeningeal disease.

• - Concurrent systemic chemotherapy to control systemic disease or bulk CNS disease allowed provided the systemic chemotherapy is not an investigational agent OR any of the following: - High-dose (> 1 g/m^2) methotrexate.

• - High-dose (> 1 g/m^2) cytarabine.

• - Fluorouracil.

• - Capecitabine.

• - Thiotepa.

• - Nitrosoureas.

• - Topotecan.

Endocrine therapy.

• - Not specified.

Radiotherapy.

• - See Disease Characteristics.

• - At least 8 weeks since prior craniospinal radiotherapy and recovered.

• - No concurrent CNS radiotherapy.

• - Concurrent radiotherapy to extra-CNS sites (e.g., painful bone metastases not in the craniospinal axis) allowed.

Surgery.

• - Not specified.

Other.

• - More than 2 weeks since prior and no other concurrent investigational agents.

- No other concurrent intra-CSF or systemic therapy for leptomeningeal disease

OBJECTIVES: Primary.

• - Determine the maximum tolerated dose (MTD) of intraventricular topotecan in young patients with neoplastic meningitis secondary to leukemia, lymphoma, or solid tumors.

• - Determine the toxic effects and dose-limiting toxicity of this drug in these patients.

• - Determine whether the MTD of this drug is also the pharmacokinetic optimal dose, defined by the topotecan lactone concentration in the cerebral spinal fluid (CSF), in these patients.

Secondary.

• - Determine, preliminarily, the antitumor activity of this drug in these patients.

• - Determine the pharmacokinetics of this drug in the CSF of these patients.

• - Correlate observed effects of post-treatment central review imaging (if feasible) with response to this drug in these patients.

OUTLINE: This is a non-randomized, dose-escalation, multicenter study.

• - Induction therapy (weeks 1-4): Patients receive topotecan intraventricularly* over 5 minutes on days 1-5 in weeks 1 and 3.

Patients then proceed to consolidation therapy in week 5. NOTE: *Patients who are willing, receive 1 intralumbar (instead of intraventricular) dose of topotecan on day 1 of week 3 only.

• - Consolidation therapy (weeks 5-10): Patients receive topotecan intraventricularly on days 1-5 in weeks 5 and 8.

Patients then proceed to maintenance therapy in week 11.

• - Maintenance therapy (weeks 11-54): Patients receive topotecan intraventricularly on days 1-5 in weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51.

Cohorts of 3-6 patients receive escalating doses of intraventricular topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded to 25 patients and the MTD is declared the pharmacokinetic optimal dose provided 23 of 25 patients treated at the MTD achieve the target pharmacokinetic parameter. PROJECTED ACCRUAL: A total of 28-49 patients will be accrued for this study within 9-24 months.